Certa Therapeutics to discuss scientific advancements at BIO conference in Philadelphia

Melbourne, Australia, 03 June 2019: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.

This year’s Biotechnology Innovation Organisation (BIO) International Convention will be attended by Certa Therapeutics and its management team including Chief Executive Officer, Professor Darren Kelly.

The BIO convention is set to take place in Philadelphia, Pennsylvania between 3-6 June 2019. It represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organisations across the United States and in more than 30 other nations.

Certa Therapeutics is currently progressing its development program for a novel therapeutic platform of precision medicines for the treatment of serious inflammatory and fibrotic diseases including systemic sclerosis (SSc) and chronic kidney disease (CKD). Certa is using genetic analysis to identify  the most suitable patients for treatment.

SSc is a rare autoimmune disease, causing inflammation and fibrosis (scarring/hardening) of the skin and other organs. There is a clear need for new innovative treatments as currently approved therapies are largely ineffective and can have significant side-effects.

There are currently no treatments available for kidney fibrosis, which presents in the majority of patients with CKD. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs.

This convention will allow the team at Certa Therapeutics to network with BIO members who are focused on the research and development of innovative healthcare and biotechnology products.

BIO includes four days of detailed programming and exhibitions, including 17,300 attendees, 126 educational sessions, more than 800 speakers, over 250 company presentations, 1,800 exhibitors, unlimited networking opportunities and unparalleled partnering.